![]() | Up a level |
Number of items: 1.
Garcia-Manero, Guillermo, Fenaux, Pierre, Al-Kali, Aref, Baer, Maria R., Sekeres, Mikkael A., Roboz, Gail J., Gaidano, Gianluca, Scott, Bart L., Greenberg, Peter, Platzbecker, Uwe, Steensma, David P., Kambhampati, Suman, Kreuzer, Karl-Anton, Godley, Lucy A., Atallah, Ehab, Collins, Robert, Jr., Kantarjian, Hagop, Jabbour, Elias, Wilhelm, Francois E., Azarnia, Nozar and Silverman, Lewis R. (2016). Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial. Lancet Oncol., 17 (4). S. 496 - 509. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1474-5488